Drug-Eluting Nanofibers
Electrospun Fiber Mesh Contraceptive
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal - Other
-
Intended Duration:
- Short-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): University of Washington, HLL Lifecare
Details
- API: Not Yet Determined
- Target: Not Yet Determined
-
Mechanism of Action:
- Cervical Mucus Changes
- Physical Barrier
- Inhibition of Sperm Motility
- Inhibition of Sperm Capacitation
- Inactive Materials: Electrospun Polymer
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: Drug-eluting nanofibers are believed to be biocompatible, readily customizable to be made of - or contain - antiviral or contraceptive compounds, and developers indicate they may be superior to existing vaginal meshes.
Product Status
Active Prototype Refinement Research
History
2012: Drug-eluting nanofibers proposed as a vaginal or transdermal drug delivery method or MPT without drug loading
2014: University of Washington development team release results of pre-clinical research on nanofiber mesh loaded with tenofovir and LNG
2017: Additional formulation and method refinement research
2019: HLL Lifecare publishes complementary research on non-MPT product, loaded with LNG and EE
2022: Univeristy of Washington publishes revised/parallel approach, using drug-eluting nanofibers to prompt tubal occlusion and permanent contraception